Prudential Financial’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-99,284
| Closed | -$1.57M | – | 2733 |
|
|
2023
Q3 | $1.57M | Buy |
99,284
+35,200
| +55% | +$632K | ﹤0.01% | 1516 |
|
|
2023
Q2 | $1.25M | Buy |
64,084
+12,706
| +25% | +$301K | ﹤0.01% | 1699 |
|
|
2023
Q1 | $1.46M | Sell |
51,378
-16,410
| -24% | -$487K | ﹤0.01% | 1532 |
|
|
2022
Q4 | $1.98M | Buy |
67,788
+2,410
| +4% | +$76.6K | ﹤0.01% | 1313 |
|
|
2022
Q3 | $1.73M | Sell |
65,378
-5,760
| -8% | -$211K | ﹤0.01% | 1420 |
|
|
2022
Q2 | $3.16M | Sell |
71,138
-48,035
| -40% | -$2.21M | 0.01% | 1127 |
|
|
2022
Q1 | $5.9M | Sell |
119,173
-16,563
| -12% | -$795K | 0.01% | 905 |
|
|
2021
Q4 | $6.91M | Sell |
135,736
-52,266
| -28% | -$2.71M | 0.01% | 862 |
|
|
2021
Q3 | $10.5M | Buy |
188,002
+10,751
| +6% | +$529K | 0.01% | 719 |
|
|
2021
Q2 | $7.59M | Sell |
177,251
-34,492
| -16% | -$1.42M | 0.01% | 871 |
|
|
2021
Q1 | $8.84M | Sell |
211,743
-24,415
| -10% | -$1.13M | 0.01% | 813 |
|
|
2020
Q4 | $11M | Buy |
236,158
+14,831
| +7% | +$694K | 0.02% | 704 |
|
|
2020
Q3 | $9.4M | Buy |
221,327
+7,763
| +4% | +$340K | 0.02% | 684 |
|
|
2020
Q2 | $10.2M | Buy |
213,564
+96,143
| +82% | +$4.8M | 0.02% | 686 |
|
|
2020
Q1 | $5.4M | Sell |
117,421
-2,273
| -2% | -$114K | 0.01% | 887 |
|
|
2019
Q4 | $7.19M | Buy |
119,694
+29,914
| +33% | +$1.78M | 0.01% | 977 |
|
|
2019
Q3 | $5.08M | Buy |
89,780
+31,257
| +53% | +$1.76M | 0.01% | 1105 |
|
|
2019
Q2 | $3.26M | Buy |
58,523
+3,817
| +7% | +$199K | 0.01% | 1350 |
|
|
2019
Q1 | $2.76M | Buy |
54,706
+21,809
| +66% | +$970K | ﹤0.01% | 1433 |
|
|
2018
Q4 | $1.33M | Buy |
32,897
+7,605
| +30% | +$392K | ﹤0.01% | 1713 |
|
|
2018
Q3 | $1.75M | Buy |
25,292
+8,404
| +50% | +$637K | ﹤0.01% | 1671 |
|
|
2018
Q2 | $1.28M | Sell |
16,888
-178,994
| -91% | -$11.3M | ﹤0.01% | 1834 |
|
|
2018
Q1 | $10.3M | Sell |
195,882
-206,240
| -51% | -$12M | 0.02% | 894 |
|
|
2017
Q4 | $21.5M | Buy |
402,122
+180,050
| +81% | +$10M | 0.03% | 609 |
|
|
2017
Q3 | $13.2M | Buy |
222,072
+197,634
| +809% | +$12M | 0.02% | 784 |
|
|
2017
Q2 | $1.93M | Sell |
24,438
-836
| -3% | -$68.4K | ﹤0.01% | 1580 |
|
|
2017
Q1 | $2.1M | Buy |
25,274
+9,330
| +59% | +$694K | ﹤0.01% | 1542 |
|
|
2016
Q4 | $1.26M | Buy |
15,944
+1,304
| +9% | +$94.7K | ﹤0.01% | 1750 |
|
|
2016
Q3 | $1.02M | Buy |
+14,640
| New | +$811K | ﹤0.01% | 1784 |
|
|
2016
Q1 | – | Sell |
-31,870
| Closed | -$2.83M | – | 2331 |
|
|
2015
Q4 | $2.83M | Buy |
+31,870
| New | +$2.52M | 0.01% | 1347 |
|
Other funds holding EGRX
BIP
Prudential Financial's EGRX Position: Q4 2023 in Review
Prudential Financial sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2023, closing a stake of 99,284 shares — an estimated $1.57M sold.
Prudential Financial first reported a position in EGRX in Q4 2015 and held it in 30 quarters. The position peaked at $21.5M in Q4 2017. 104 funds tracked by Wall St. Rank hold EGRX as of Q4 2023.
- Prudential Financial reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Prudential Financial sold 99,284 Eagle Pharmaceuticals, Inc. shares in Q4 2023, an estimated $1.57M.
- Prudential Financial first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 30 quarters.
- Prudential Financial's Eagle Pharmaceuticals, Inc. position peaked at $21.5M in Q4 2017.
- 104 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2023.
Based on Prudential Financial's 13F filing for Q4 2023, filed 13 Feb 2024.